Chloramphenicol is a potent antibiotic used in humans for eye infections, typhoid and cholera, according to a StatPearls article in the National Library of Medicine.

Celsus Therapeutics will acquire Volution Immuno Pharmaceuticals (VIP), creating a combined company focused on developing and commercializing treatments for orphan autoimmune and inflammatory ...

Celsus Therapeutics and Volution Immuno Pharmaceuticals SA today announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno ...

British drugmaker Celsus Therapeutics Plc's U.S.-listed shares plunged as much as 83 percent after the company's skin cream failed the main goal of a mid-stage study.

Celsus Therapeutics Plc and Volution Immuno Pharmaceuticals SA today announced that Celsus has entered into a securities purchase agreement for a private placement with a select group of investors ...

Broadfin Capital, Celsus: Broadfin Capital, managed by Kevin Kotler, just disclosed a position in Celsus Therapeutics (OTCQB: CLSXY).According to a SEC filing, Broadfin purchased around 3.5 ...

Celsus Therapeutics and Volution Immuno Pharmaceuticals SA have announced that they have entered into a Definitive Exchange Agreement, pursuant to which privately-held Volution Immuno Pharmaceuticals ...

NEW YORK and LONDON, Oct. 24, 2013 (GLOBE NEWSWIRE) -- Celsus Therapeutics (OTCQB:CLSXY), an emerging growth, development-stage biopharmaceutical company, announces the appointment of Pablo ...

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! NEW YORK, NY and LONDON--(Marketwired - May 01, 2013) - Celsus Therapeutics (OTCQB: MRRBY), an emerging ...